



Published in final edited form as:

J Neurovirol. 2016 June ; 22(3): 327–335. doi:10.1007/s13365-015-0401-8.

Expression of *CHRFAM7A* and *CHRNA7* in neuronal cells and post-mortem brain of HIV-infected patients: *Considerations for HIV-Associated Neurocognitive Disorder*

Félix M. Ramos¹, Manuel Delgado-Vélez¹, Ángel L. Ortiz², Carlos A. Báez-Pagán¹, Orestes Quesada³, and José A. Lasalde-Dominicci^{1,*}

¹Department of Biology, the University of Puerto Rico, Río Piedras Campus, San Juan, Puerto Rico 00931-3360

²Department of Chemistry and the University of Puerto Rico, Río Piedras Campus, San Juan, Puerto Rico 00931-3360

³Department of Physical Sciences, University of Puerto Rico, Río Piedras Campus, San Juan, Puerto Rico 00931-3360

Abstract

Despite the recent advances in antiretroviral therapy, HIV-1 remains a global health threat. HIV-1 affects the central nervous system by releasing viral proteins that trigger neuronal death, neuroinflammation, and promotes alterations known as HIV-associated neurocognitive disorders (HAND). This disorder is not fully understood and no specific treatments are available. Recently, we demonstrated that the HIV-1 envelope protein gp120_{IIIB} induces a functional upregulation of the $\alpha 7$ -nicotinic acetylcholine receptor ($\alpha 7$) in neuronal cells. Furthermore, this upregulation promotes cell death that can be abrogated with receptor antagonists, suggesting that $\alpha 7$ may play an important role in the development of HAND. The partial duplication of the gene coding for the $\alpha 7$, known as *CHRFAM7A*, negatively regulates $\alpha 7$ expression but its role in HIV infection has not been studied. Hence, we studied both *CHRNA7* and *CHRFAM7A* regulation pattern in various gp120_{IIIB} *in vitro* conditions. In addition, we measured *CHRNA7* and *CHRFAM7A* expression levels in postmortem brain samples from patients suffering from different stages of HAND. Our results demonstrate the induction of *CHRNA7* expression accompanied by a significant down-regulation of *CHRFAM7A* in neuronal cells when exposed to pathophysiological concentrations of gp120_{IIIB}. Our results suggest a dysregulation of *CHRFAM7A* and *CHRNA7* expression in the basal ganglia from postmortem brain samples of HIV+ subjects and expand the current knowledge about the consequences of HIV infection in the brain.

Keywords

gp120; HIV; HAND; acetylcholine receptor; CHRNA7; CHRFAM7A

*Correspondence to: José A. Lasalde-Dominicci, Phone: (787) 764-0000, Ext. 2765, FAX: (787) 764-3875, jlasalde@gmail.com. Orestes Quesada, Phone: (787) 764-0000, Ext. 4752, FAX: (787) 759-6885, quesada.orestes@gmail.com

Conflict of interest: The authors declare that they have no competing interests.

Introduction

The human immunodeficiency virus type 1 (HIV-1) is considered one of the principal pandemics of the twenty-first century with approximately 34 million of subjects infected globally (Joint United Nations Programme on HIV/AIDS (UNAIDS 2013). In addition to developing acquired immunodeficiency syndrome (AIDS), infected individuals may also develop neurological complications known as HIV-associated neurocognitive disorders (HAND). HAND includes asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD) (Antinori et al. 2007). HAD results in disabling cognitive impairment accompanied by motor dysfunction, speech problems, and overt behavioral changes (González-Scarano and Martín-García 2005; Clifford and Ances 2013). Although the incidence of HAD has decreased (Bhaskaran et al. 2008), the prevalence of HAND, mostly of the milder forms of neurocognitive impairment (ANI and MND), could be as high as 50% of patients (Sacktor et al. 2002; Cysique et al. 2004; Heaton et al. 2011). Moreover, the high prevalence of HAND occurs despite administration of combined antiretroviral therapy (cART) (Mothobi and Brew 2012). For instance, under cART, HAND persists despite systemic or brain viral load reduction or control (Cysique and Brew 2011; Koneru et al. 2014).

HIV is unable to infect neurons due to their lack of primary CD4 receptors, however, neuronal expression of both CCR5 and CXCR4 secondary receptors could allow viral interactions (Hesselgesser et al. 1997). Several hypotheses have emerged to explain the cause of HAND including the neurotoxic properties of viral proteins and the severe uncontrolled chronic neuroinflammation (Kong et al. 1996; Heaton et al. 2011). Particularly, the HIV-1 viral envelope protein gp120 has been reported to have various neurotoxic properties *in vitro* and *in vivo* including the inhibition of adult neural progenitor cells proliferation, neuronal damage and induction of apoptosis, and cell death of human neuronal cells (Toggas et al. 1994; Meucci and Miller 1996; Hesselgesser et al. 1998; Jana and Pahan 2004; Bardi et al. 2006; Okamoto et al. 2007; Ballester et al. 2012). Moreover, the severity of brain damage correlates with gp120 levels (Desai et al. 2013).

The alpha7 nicotinic acetylcholine receptor ($\alpha 7$) is one of the most common receptors expressed in the mammalian brain (Dani and Lester 2001). The $\alpha 7$ subunit is encoded by the *CHRNA7* gene in chromosome 15, and is composed of 10 exons (Gault et al. 1998). Interestingly, the *CHRNA7* has a counterpart gene named *CHRFAM7A* (Gault et al. 1998). The *CHRFAM7A* gene product, dup $\alpha 7$, exerts a regulatory/inhibitory role on the $\alpha 7$ ion channel activity and expression (de Lucas-Cerrillo et al. 2011; Araud et al. 2011), although a recent work has challenged these results showing that dup $\alpha 7$ and $\alpha 7$ can form functional heteropentamers with altered responses to choline and varenicline (Wang et al. 2014). This may be due to differences in the expression system used that could influence ion channel functionality and assembly –the first study used oocytes while the most recent used Neuro2a cells–, and the use of $\alpha 7$'s chaperone RIC-3 in Neuro2a cells but not in oocytes. For a comprehensive review about dup $\alpha 7$ refer to (Costantini et al. 2014). Notwithstanding, although the $\alpha 7$ has been amply studied in CNS, very little is known about its role in the neuropathology of HIV infection. We recently demonstrated that gp120_{III B} induces a functional $\alpha 7$ upregulation in neuronal cells and that the expression of gp120_{III B} in the brain

of a transgenic mouse model also induces the overexpression of $\alpha 7$ in the brain, particularly in the striatum, basal ganglia's primary input (Ballester et al. 2012). Moreover, we found that the activation of upregulated $\alpha 7$ in these neuronal cells induces cell death in a calcium-dependent manner (Ballester et al. 2012). In light of the possible role of $\alpha 7$ in the HIV neuropathogenesis, we evaluated the mRNA expression patterns of *CHRNA7*, *CHRFAM7A* and the expression ratio *CHRNA7:CHRFAM7A* upon gp120_{III B} application in a human neuronal cell line and in post-mortem brain samples from HIV-infected patients expressing different severity stages of neurocognitive impairment.

Materials and methods

Reagents

All reagents were purchased from Sigma Aldrich unless otherwise specified.

Cell culture and treatments

SH-SY5Y neuronal cell line was obtained from ATCC (Manassas, VA). Cells were incubated at 37 °C with 5% CO₂ in DMEM/F-12 media supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1.2 g of NaHCO₃. Cultures were performed in 12-well plates followed by treatments with gp120_{III B} (Fitzgerald Industries International, Concord, MA) at 0.0015, 0.015, 0.15, 1.5 or 15 nM for the indicated time. For time-dependent experiments, the concentration of gp120_{III B} was 0.15 nM. The CXCR4 antagonist, AMD3100 (EMD Chemicals, Inc., Gibbstown, NJ), was used at 1 μ M and added 10 min prior to gp120_{III B} application. The range of gp120 concentrations tested here were based on gp120 quantification studies using plasma, serum and tissues from HIV-infected subjects (Gilbert et al. 1991; Oh et al. 1992; Santosuosso et al. 2009; Rychert et al. 2010). To our knowledge there is no quantification studies to determine gp120 in the brain or cerebrospinal fluid (CSF). However, there is a robust body of evidence demonstrating that indeed gp120 is present in the central nervous system and CSF, even though no evidence of quantification is available in the literature (Buzy et al. 1989; Rolfs and Schumacher 1990; Ruta et al. 1998; Cashion et al. 1999; Jones et al. 2000; Ohagen et al. 2003; Pillai et al. 2006). Moreover, the existence of anti-gp120 antibodies in the CNS unequivocally attests to its presence (Lucey et al. 1993; Di Stefano et al. 1996; Trujillo et al. 1996).

RNA extraction and quantitative RT-PCR assay

In SH-SY5Y neuronal cells, total RNA samples were extracted using TriZol Reagent (Invitrogen Corporation, Carlsbad, CA). To eliminate possible genomic contamination, extracted RNA was treated with DNase using the Ambion DNA free kit (Ambion, Austin, TX). Quantification of total RNA was performed using a Nanodrop system (Thermo Scientific, Waltham, MA). The cDNA synthesis was carried out using 0.75 μ g of total RNA with the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA) following the manufacturer's instructions. After optimization of the PCR conditions, real-time PCR experiments were performed using the iQ™ SYBR® Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA) in a Mastercycler® Ep Realplex Thermal Cycler (Eppendorf, NY). *CHRNA7* and GAPDH primers were used at a final concentration of 400 nM, *CHRFAM7A* primers at 100 nM together with 100 ng of cDNA. Primers were designed

using IDT Designer Software (Integrated DNA Technologies). The primers employed to amplify the genes of interest from cells and tissue samples were the following: *CHRNA7* forward, 5'-GCTCCGGGACTCAACATG-3'; reverse, 5'-GGGATTGTAGTTCTTGACCAGC-3'; *CHRFAM7A* forward, 5'-CCGAAGTTACTGGCCTCTATC-3' reverse, 5'-CTGAGTCGTGTAGATAAGCTCTC-3', and for GAPDH: forward, 5'-GCTCTCTGCTCCTCCTGTTC-3', reverse, 5'-GACTCCGACCTTCACCTTCC-3'. All primers were used with an annealing temperature of 55 °C.

Tissue processing and RNA extraction

Post-mortem brain tissues from HIV-infected patients were obtained from the Texas NeuroAIDS Research Center (IRB#: 98-402), California NeuroAIDS Tissue Network (IRBs#: 00000353, 00000354, 00000355, and 000002758), and UCLA National Neurological AIDS Bank (IRB#: 10000525) Tissue samples were pulverized in liquid nitrogen under RNase free conditions. RNA extraction was performed using TriZol reagent (Invitrogen) following manufacturer's instructions. The RNA integrity was assayed in 1% electrophoresis agarose gel. Samples were processed for qRT-PCR as described above.

Statistical analyses

To evaluate the statistical significance of changes in expression levels of *CHRNA7* and *CHRFAM7A* in neuronal cells we used One-way ANOVA followed by Holm-Sidak's multiple comparison test which allowed corrections for multiple comparisons with a fixed alpha value (0.05). Spearman correlation was used to identify correlations between *CHRFAM7A* and *CHRNA7* expression levels in neuronal cells. The detected outliers were excluded from analysis. Statistical analysis was conducted using the GraphPad Prism 6 software (GraphPad Software, San Diego, CA, www.graphpad.com).

Results

gp120_{IIIb} promotes the downregulation of *CHRFAM7A* in neuronal cells

Neuronal cells were exposed to various concentrations of gp120_{IIIb} including those within the pathophysiological range quantified in HIV-infected patients (0.0015, 0.015 and 0.15 nM) (Gilbert et al. 1991; Oh et al. 1992; Santosuosso et al. 2009; Rychert et al. 2010). Measurements of *CHRNA7* and *CHRFAM7A* levels after addition of pathophysiological relevant gp120_{IIIb} concentrations show that the *CHRFAM7A* was downregulated in a dose-dependent manner, and that the expression of *CHRNA7* was induced (Fig. 1a). Noteworthy is that this effect in *CHRFAM7A* expression levels is sustained even when supraphysiological concentrations of gp120_{IIIb} were used (15 nM). Further evaluation shows that *CHRNA7:CHRFAM7A* expression ratios increase with the gp120_{IIIb} treatment (Fig. 1b).

A pathophysiological dose of gp120_{IIIb} time-dependently dysregulates *CHRNA7* and *CHRFAM7A* expression in neuronal cells

CXCR4 is a coreceptor employed by HIV to infect immune cells and is expressed by neurons (Hesseltger et al. 1997). Neuronal cells exposed to gp120_{IIIb} (0.15 nM) at

different time points showed that the $\alpha 7$ gene, *CHRNA7*, was upregulated after 12 hours post gp120_{IIIb} exposure whereas *CHRFAM7A* downregulation initiated as early as 15 minutes post gp120_{IIIb} application, and lasts 24 hours (Fig. 2a). Moreover, a ratio analysis demonstrates an early increase in the *CHRNA7:CHRFAM7A* expression (Fig 2b).

A CXCR4 antagonist abrogates the gp120_{IIIb}-induced dysregulation of *CHRNA7*

To determine whether the *CHRNA7* and *CHRFAM7A* dysregulation depends on CXCR4 stimulation, an antagonist (AMD3100) was applied prior to gp120_{IIIb} addition. Our results show that CXCR4 blockade abrogates gp120_{IIIb}-induced upregulation of *CHRNA7* (Fig. 3). Unexpectedly, *CHRFAM7A* was downregulated by AMD3100 in the absence of gp120_{IIIb} (Fig 3a).

The *CHRNA7* and *CHRFAM7A* expression levels in the basal ganglia of HIV-infected subjects

It is known that the basal ganglia is an area of the brain that is severely affected in HIV-infected patients (Woods et al. 2009) and contain some of the brain's highest viral load (Kure et al. 1990). We recently found that the *CHRNA7* gene product, $\alpha 7$, is upregulated in the striatum (a component of the basal ganglia) of mice expressing gp120_{IIIb} in the brain (Ballester et al. 2012). Here we examined *CHRNA7*, *CHRFAM7A*, and *CHRNA7:CHRFAM7A* levels in the basal ganglia of HIV-infected post mortem basal ganglia samples representing different stages of neurological impairment. Table 1 summarizes the subject characteristics. Evaluation of *CHRFAM7A* and *CHRNA7* genes in HIV+ patients shows that *CHRNA7* is significantly expressed at higher levels than *CHRFAM7A* (Fig 4a), which is consistent with what we observed in the neuronal cells (Fig. 1a). The *CHRNA7:CHRFAM7A* ratio of the HIV+ group was increased in these patients (Fig. 4b). Examination of *CHRNA7* levels in basal ganglia from HIV-infected subjects suffering from different stages of cognitive impairment showed no significant differences (Fig. 4c). In terms of *CHRFAM7A*, at first glance, patients with normal cognition are not different from HIV- (Fig. 4d) but detailed examination of the distribution of *CHRFAM7A* levels in normal cognition patients demonstrate two distinguishable groups identified as subgroups A and B (Fig. 4d). Evaluation of these groups revealed that subgroup A is upregulated while subgroup B is downregulated for *CHRFAM7A* expression (Fig. 4d). Furthermore, examination of *CHRFAM7A* levels in the MCMD group suggests that only HIV+ patients with low *CHRFAM7A* levels develop MCMD (Fig. 4e). Ratio analysis demonstrates no significant differences in the *CHRNA7:CHRFAM7A* expression ratio in the basal ganglia of these patients and a linear trend analysis showed a non-significant ($P=0.08$) increment in *CHRNA7:CHRFAM7A* with increasing cognitive impairment severity (Fig. 4f).

Discussion

HIV-infected patients suffer from cognitive disorders associated with the infection. In a previous report we demonstrated that gp120_{IIIb} is capable of inducing a functional upregulation of the $\alpha 7$ in neuronal cells and that this upregulation promotes cell death in a calcium-dependent manner (Ballester et al. 2012). In the current study, we expand these

observations demonstrating that gp120_{IIIb} induces the upregulation of the $\alpha 7$ gene *CHRNA7* and the downregulation of its partial duplication, *CHRFAM7A*, in neuronal cells. The significant reduction in *CHRFAM7A* expression could imply that dup $\alpha 7$'s dominant negative effect on $\alpha 7$'s functionality may be concomitantly reduced, thus providing a modulatory/regulatory explanation for our previous observations (Ballester et al. 2012). Because of dup $\alpha 7$'s dominant negative regulatory effect on $\alpha 7$, we evaluated the *CHRNA7:CHRFAM7A* ratio as indicative of the $\alpha 7$ functionality and found that gp120_{IIIb} indeed does modify the ratio. In our study, we also used different concentrations of gp120_{IIIb} to better understand its effects on *CHRNA7* and *CHRFAM7A* expression. Our results show that the greatest observed reduction in *CHRFAM7A* expression together with a *CHRNA7* induction occurs within the pathophysiological range of gp120_{IIIb} documented for HIV-infected patients.

We also studied the kinetics of the gp120_{IIIb}-induced *CHRNA7* and *CHRFAM7A* dysregulation. Our results demonstrate that the gp120_{IIIb} first induces a reduction in *CHRFAM7A* expression (15 min) followed by *CHRNA7* induction (12 h), shedding light on the regulatory/modulatory mechanism behind the $\alpha 7$ upregulation which points to an early regulatory mechanism (before 15 min) by the *CHRFAM7A* gene. These results, together with our previous published observations demonstrating that the functional upregulation of $\alpha 7$ in neuronal cells promote cell death and that the $\alpha 7$ upregulation appears to be restricted to the basal ganglia (Ballester et al. 2012), are consistent with: (i) the neuronal apoptosis and cell death in the presence of gp120_{IIIb} ($\times 4$), gp120 R5, and supernatants containing HIV-1 (Hesseltger et al. 1998; Catani et al. 2000; Xu et al. 2004), (ii) the neuronal apoptosis identified in postmortem brain from adults and pediatric HIV-infected patients (Adle-Biassette et al. 1995; Gelbard et al. 1995), (iii) the basal ganglia neuronal density reduction in HIV-infected patients (Everall et al. 1995), (iv) autopsy studies of patients with HAD showing that the greatest burden of neuropathology is found in the basal ganglia (Brew et al. 1995), (v) the large accumulation of gp120 in humans' basal ganglia (Jones et al. 2000), and (vi) the neuronal dysfunction and cellular destruction identified in a transgenic mice expressing gp120 in the brain (Corboy et al. 1992; Toggas et al. 1994; Berrada et al. 1995).

Although neurons do not express CD4, they express functional CXCR4 and CCR5 coreceptors enabling gp120 to interact with them and activate signaling pathways leading to neuronal cell death (Kaul et al. 2005; Kaul et al. 2007). The role of CXCR4 in the gp120-mediated neurotoxicity can be direct, through the activation of neuronal receptors by gp120; or indirect through the stimulation of glial cells leading to release of neurotoxic factors (Ghafouri et al. 2006). The activation of CXCR4 by SDF-1 α (CXCR4 endogenous agonist) or gp120 has been implicated in the mechanism for neuronal dysfunction during HAD (Hesseltger et al. 1998; Zheng et al. 1999). Herein we report alterations in the gene expression of a cholinergic receptor and its partial duplication which are both amply distributed through the brain. Dysregulation of these genes under neuropathological settings is not new. For instance, the ratio of *CHRNA7:CHRFAM7A* mRNA levels is different in bipolar subjects when compared to unaffected controls (De Luca et al. 2006). Moreover, *in vitro* studies have demonstrated that two pro-inflammatory mediators characteristic of HIV-I infection, LPS and IL-1 β , decrease *CHRFAM7A* expression leading to the suggestion that chronic pro-inflammatory responses might change the *CHRFAM7A:CHRNA7* expression

ratio (Benfante et al. 2011; van der Zanden et al. 2012). gp120_{IIIB} is unable to promote *CHRNA7:CHRFAM7A* alterations in the presence of AMD3100, an antagonist of CXCR4, suggesting that the gp120_{IIIB}-induced *CHRNA7:CHRFAM7A* dysregulation is CXCR4-dependent.

The cognitive impairments observed in HIV-infected subjects are the consequence of neurological alterations in the brain that compromise neural tracts resulting in significant damage and alterations of specific areas. The basal ganglia, which is one of the most severely affected areas in these patients (Berger and Nath 1997; Berger and Arendt 2000; Berger et al. 2000; von Giesen et al. 2001; Woods et al. 2009), contains cholinergic neurons and interneurons that express $\alpha 7$ (Azam et al. 2003; Bonsi et al. 2011). To better understand the clinical implications of our findings, analysis of *CHRNA7* and *CHRFAM7A* genes were performed on post-mortem basal ganglia samples from HIV-infected individuals with different levels of neurological impairment severity. Our results demonstrate that regardless of the neurological impairment severity, the *CHRNA7* was not significantly altered as compared to HIV- subjects. However, comparing the expression of the *CHRNA7* and *CHRFAM7A* genes within HIV-infected patients reveals that the *CHRNA7* expression is significantly increased in these patients (Fig. 4a). Interestingly, a closer look at the *CHRFAM7A* gene expression levels revealed two distinct populations within the normal cognition group: subgroup A and B. Of note, a significant increase was detected in the expression of the *CHRFAM7A* gene in subgroup A when compared to the HIV- group and subgroup B, and a significant reduction in the expression of *CHRFAM7A* in subgroup B was detected when compared to the HIV- group and subgroup A. In addition, comparing the *CHRFAM7A* expression in both subgroups reveals a statistically significant difference. A provocative hypothesis on the existence of these two discernible subgroups within the normal cognition group is that the patients exhibiting elevated levels of *CHRFAM7A* are less likely of suffering from HIV-associated cognition problems, and those with low levels of *CHRFAM7A*, within sub-group B, are more susceptible to develop neurological impairment as lower *CHRFAM7A* expression levels could imply a potentiation of the $\alpha 7$ receptor expression, increased calcium influx, and ultimate neuronal cell death (de Lucas-Cerrillo et al. 2011; Araud et al. 2011; Ballester et al. 2012). Because the tissues were collected before patients presenting ANI were distinguished from patients displaying normal cognition, subgroups A and B could comprise patients with either normal cognition or ANI. It is tempting to hypothesize that subgroup A comprise patients with normal cognition, and subgroup B comprise patients that presented ANI as patients presenting ANI are known to progress to more severe stages (Grant et al. 2014). Taking this into account, our results may imply that alterations in the expression of *CHRNA7* and *CHRFAM7A*, or the *CHRNA7:CHRFAM7A* ratio might be detrimental to the cognitive performance of these patients.

In this study we tested the hypothesis that higher levels of neurological impairment could be associated with alterations in *CHRNA7* or *CHRFAM7A* expression levels. Whether this dysregulation is responsible for the destruction of cholinergic neurons within the basal ganglia of HIV-infected patients remains to be determined. However, the available evidence points in that direction. For instance, (i) the basal ganglia of HIV-infected patients is compromised (Berger and Nath 1997; Berger et al. 2000; von Giesen et al. 2001; Woods et

al. 2009), (ii) the $\alpha 7$ upregulation in the basal ganglia of transgenic mice expressing gp120 in the brain predispose this area to cell death events similar to what was detected in $\alpha 7$ -upregulated neuronal cells (Ballester et al. 2012). Together, this evidence lead us to suggest that the alterations in the *CHRNA7:CHRFAM7A* expression might be implicated in the basal ganglia alterations observed in HIV-infected subjects with neurological impairments. This interpretation is supported by several lines of evidence showing that the motor dysfunction suffered by subjects, under pathological circumstances, involve compromised basal ganglia interneurons (Bonsi et al. 2011) reminiscent of MCMD-suffering patients.

In conclusion, we showed that gp120_{III B} is capable of dysregulating the *CHRNA7/CHRFAM7A* expression in neuronal cells. Moreover, this dysregulation was detected in postmortem brain samples recovered from HIV-infected patients with different stages of HAND. The present study is limited in that the results from HIV+ patients basal ganglia may be hindered by the lack of statistical power to detect small changes in expression levels as statistically significant given the dispersion in the data; and that the normal cognition group may actually include HIV+ patients that presented asymptomatic neurocognitive impairment (ANI) because the tissues were collected before ANI was established as a classification category of HIV-induced neurocognitive disorders. Nevertheless, our results raises fundamental questions about the role of $\alpha 7$ and dup $\alpha 7$ in HIV-induced neurological disorders and warrants further statistically powered investigations using an increased number of brain samples from HIV-infected subjects under different stages of HAND. In addition, further studies aimed at exploring the CCR5 tropic gp120 (gp120_{JRFL}) effects on $\alpha 7$ expression in neuronal cells are warranted. It would be interesting to determine whether CCR5 stimulation influences $\alpha 7$ expression as occurs with the CXCR4 tropic-specific gp120_{III B}. In fact, it is known that activation of these G-protein coupled receptors produce similar signaling pathways (Davis et al. 1997; Lee et al. 2003) that, in the presence of gp120, could lead to death of neuronal cells (Catani et al. 2000), therefore, it would not be surprising that both gp120s produce similar responses.

Acknowledgments

We are very grateful for Dr. Valerie Wojna's valuable suggestions and in depth review of this manuscript. We appreciate the National NeuroAIDS Tissue Consortium (NNTC) and the Data Coordinating Center (DCC) which is a project funded by the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke under the following grants: U24MH100928 (California NeuroAIDS Tissue Network), U24MH100930 (Texas NeuroAIDS Research Center), and U24MH100929 (UCLA National Neurological AIDS Bank). This research was supported by the National Institutes of Health-NINDS (2U54NS43011 to José A. Lasalde-Dominicci), the RISE Program from NIGMS (2R25GM061151 to Manuel Delgado-Vélez and Orestes Quesada) and MARC Program from NIGMS (5T34GM007821 to Orestes Quesada and Felix M. Ramos). Research reported in this publication was supported by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under Award Number U54MD007587 (Carlos A. Báez-Pagán). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

- Adle-Biassette H, Levy Y, Colombel M, et al. Neuronal apoptosis in HIV infection in adults. *Neuropathol Appl Neurobiol.* 1995; 21:218–227. [PubMed: 7477730]
- Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology.* 2007; 69:1789–1799. DOI: 10.1212/01.WNL.0000287431.88658.8b [PubMed: 17914061]

- Araud T, Graw S, Berger R, et al. The chimeric gene *CHRFAM7A*, a partial duplication of the *CHRNA7* gene, is a dominant negative regulator of $\alpha 7^*$ nAChR function. *Biochem Pharmacol*. 2011; 82:904–914. DOI: 10.1016/j.bcp.2011.06.018 [PubMed: 21718690]
- Azam L, Winzer-Serhan U, Leslie FM. Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. *Neuroscience*. 2003; 119:965–977. [PubMed: 12831856]
- Ballester LY, Capó-Vélez CM, García-Beltrán WF, et al. Up-regulation of the neuronal nicotinic receptor $\alpha 7$ by HIV glycoprotein 120: potential implications for HIV-associated neurocognitive disorder. *J Biol Chem*. 2012; 287:3079–3086. DOI: 10.1074/jbc.M111.262543 [PubMed: 22084248]
- Bardi G, Sengupta R, Khan MZ, et al. Human immunodeficiency virus gp120-induced apoptosis of human neuroblastoma cells in the absence of CXCR4 internalization. *J Neurovirol*. 2006; 12:211–218. DOI: 10.1080/13550280600848373 [PubMed: 16877302]
- Benfante R, Antonini RA, De Pizzol M, et al. Expression of the $\alpha 7$ nAChR subunit duplicate form (*CHRFAM7A*) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. *J Neuroimmunol*. 2011; 230:74–84. DOI: 10.1016/j.jneuroim.2010.09.008 [PubMed: 20926142]
- Berger JR, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. *J Psychopharmacol Oxf Engl*. 2000; 14:214–221.
- Berger JR, Nath A. HIV dementia and the basal ganglia. *Intervirology*. 1997; 40:122–131. [PubMed: 9450229]
- Berger JR, Nath A, Greenberg RN, et al. Cerebrovascular changes in the basal ganglia with HIV dementia. *Neurology*. 2000; 54:921–926. [PubMed: 10690987]
- Berrada F, Ma D, Michaud J, et al. Neuronal expression of human immunodeficiency virus type 1 env proteins in transgenic mice: distribution in the central nervous system and pathological alterations. *J Virol*. 1995; 69:6770–6778. [PubMed: 7474088]
- Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. *Ann Neurol*. 2008; 63:213–221. DOI: 10.1002/ana.21225 [PubMed: 17894380]
- Bonsi P, Cuomo D, Martella G, et al. Centrality of striatal cholinergic transmission in Basal Ganglia function. *Front Neuroanat*. 2011; 5:6.doi: 10.3389/fnana.2011.00006 [PubMed: 21344017]
- Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. *Ann Neurol*. 1995; 38:563–570. DOI: 10.1002/ana.410380404 [PubMed: 7574452]
- Buzy JM, Brenneman DE, Siegal FP, et al. Cerebrospinal fluid from cognitively impaired patient with acquired immunodeficiency syndrome shows gp120-like neuronal killing in vitro. *Am J Med*. 1989; 87:361–362. [PubMed: 2549792]
- Cashion MF, Banks WA, Bost KL, Kastin AJ. Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. *Brain Res*. 1999; 822:26–33. [PubMed: 10082880]
- Catani MV, Corasaniti MT, Navarra M, et al. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors. *J Neurochem*. 2000; 74:2373–2379. [PubMed: 10820198]
- Clifford DB, Ances BM. HIV-associated neurocognitive disorder. *Lancet Infect Dis*. 2013; 13:976–986. DOI: 10.1016/S1473-3099(13)70269-X [PubMed: 24156898]
- Corboy JR, Buzy JM, Zink MC, Clements JE. Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice. *Science*. 1992; 258:1804–1808. [PubMed: 1465618]
- Costantini TW, Dang X, Coimbra R, et al. *CHRFAM7A*, a human-specific and partially duplicated $\alpha 7$ -nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury. *J Leukoc Biol*. 2014; doi: 10.1189/jlb.4RU0814-381R
- Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. *J Neurovirol*. 2011; 17:176–183. DOI: 10.1007/s13365-011-0021-x [PubMed: 21416169]
- Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients

- across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. *J Neurovirol.* 2004; 10:350–357. DOI: 10.1080/13550280490521078 [PubMed: 15765806]
- Dani, JA.; Lester, RA. eLS. John Wiley & Sons, Ltd; 2001. *Nicotinic Acetylcholine Receptors in Neurons.*
- Davis CB, Dikic I, Unutmaz D, et al. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. *J Exp Med.* 1997; 186:1793–1798. [PubMed: 9362541]
- de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, et al. Function of partially duplicated human $\alpha 7$ nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response. *J Biol Chem.* 2011; 286:594–606. DOI: 10.1074/jbc.M110.180067 [PubMed: 21047781]
- De Luca V, Likhodi O, Van Tol HHM, et al. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. *Acta Psychiatr Scand.* 2006; 114:211–215. DOI: 10.1111/j.1600-0447.2006.00785.x [PubMed: 16889592]
- Desai, M.; Hu, N.; Byrd, D.; Yu, Q. Neuronal Apoptosis in HIV-1-Associated Central Nervous Diseases and Neuropathic Pain. In: Rudner, J., editor. *Apoptosis InTech.* 2013.
- Di Stefano M, Gray F, Leitner T, Chioldi F. Analysis of ENV V3 sequences from HIV-1-infected brain indicates restrained virus expression throughout the disease. *J Med Virol.* 1996; 49:41–48. DOI: 10.1002/(SICI)1096-9071(199605)49:1<41::AID-JMV7>3.0.CO;2-K [PubMed: 8732858]
- Everall I, Barnes H, Spargo E, Lantos P. Assessment of neuronal density in the putamen in human immunodeficiency virus (HIV) infection. Application of stereology and spatial analysis of quadrats. *J Neurovirol.* 1995; 1:126–129. [PubMed: 9222349]
- Gault J, Robinson M, Berger R, et al. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). *Genomics.* 1998; 52:173–185. DOI: 10.1006/geno.1998.5363 [PubMed: 9782083]
- Gelbard HA, James HJ, Sharer LR, et al. Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy. *Neuropathol Appl Neurobiol.* 1995; 21:208–217. [PubMed: 7477729]
- Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. *Retrovirology.* 2006; 3:28. doi: 10.1186/1742-4690-3-28 [PubMed: 16712719]
- Gilbert M, Kirihara J, Mills J. Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120. *J Clin Microbiol.* 1991; 29:142–147. [PubMed: 1993748]
- González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. *Nat Rev Immunol.* 2005; 5:69–81. DOI: 10.1038/nri1527 [PubMed: 15630430]
- Grant I, Franklin DR, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. *Neurology.* 2014; 82:2055–2062. DOI: 10.1212/WNL.0000000000000492 [PubMed: 24814848]
- Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol.* 2011; 17:3–16. DOI: 10.1007/s13365-010-0006-1 [PubMed: 21174240]
- Hesselgesser J, Halks-Miller M, DeVecchio V, et al. CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. *Curr Biol CB.* 1997; 7:112–121. [PubMed: 9024623]
- Hesselgesser J, Taub D, Baskar P, et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. *Curr Biol CB.* 1998; 8:595–598. [PubMed: 9601645]
- Jana A, Pahan K. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. *J Neurosci Off J Soc Neurosci.* 2004; 24:9531–9540. DOI: 10.1523/JNEUROSCI.3085-04.2004
- Joint United Nations Programme on HIV/AIDS (UNAIDS). *Global Report: UNAIDS Report on global AIDS Epidemic 2013.* 2013
- Jones MV, Bell JE, Nath A. Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. *AIDS Lond Engl.* 2000; 14:2709–2713.

- Kaul M, Ma Q, Medders KE, et al. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. *Cell Death Differ.* 2007; 14:296–305. DOI: 10.1038/sj.cdd.4402006 [PubMed: 16841089]
- Kaul M, Zheng J, Okamoto S, et al. HIV-1 infection and AIDS: consequences for the central nervous system. *Cell Death Differ.* 2005; 12(Suppl 1):878–892. DOI: 10.1038/sj.cdd.4401623 [PubMed: 15832177]
- Koneru R, Olive MF, Tyor WR. Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. *J Neurovirol.* 2014; 20:9–17. DOI: 10.1007/s13365-013-0223-5 [PubMed: 24415129]
- Kong LY, Wilson BC, McMillian MK, et al. The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. *Cell Immunol.* 1996; 172:77–83. DOI: 10.1006/cimm.1996.0217 [PubMed: 8806809]
- Kure K, Weidenheim KM, Lyman WD, Dickson DW. Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration. *Acta Neuropathol (Berl).* 1990; 80:393–400. [PubMed: 2239151]
- Lee C, Liu QH, Tomkowicz B, et al. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. *J Leukoc Biol.* 2003; 74:676–682. DOI: 10.1189/jlb.0503206 [PubMed: 12960231]
- Lucey DR, VanCott TC, Loomis LD, et al. Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop). *J Acquir Immune Defic Syndr.* 1993; 6:994–1001. [PubMed: 7688046]
- Meucci O, Miller RJ. gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-beta1. *J Neurosci Off J Soc Neurosci.* 1996; 16:4080–4088.
- Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. *Curr Opin Infect Dis.* 2012; 25:4–9. DOI: 10.1097/QCO.0b013e32834ef586 [PubMed: 22156897]
- Ohagen A, Devitt A, Kunstman KJ, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. *J Virol.* 2003; 77:12336–12345. [PubMed: 14581570]
- Oh SK, Cruikshank WW, Raina J, et al. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. *J Acquir Immune Defic Syndr.* 1992; 5:251–256. [PubMed: 1740750]
- Okamoto S, Kang YJ, Brechtel CW, et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. *Cell Stem Cell.* 2007; 1:230–236. DOI: 10.1016/j.stem.2007.07.010 [PubMed: 18371353]
- Pillai SK, Pond SLK, Liu Y, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. *Brain J Neurol.* 2006; 129:1872–1883. DOI: 10.1093/brain/awl136
- Rolfs A, Schumacher HC. Early findings in the cerebrospinal fluid of patients with HIV-1 infection of the central nervous system. *N Engl J Med.* 1990; 323:418–419. DOI: 10.1056/NEJM199008093230614 [PubMed: 2370895]
- Ruta SM, M tusa R, Cernescu CC. Cerebrospinal fluid western Blot profiles in the evolution of HIV-1 pediatric encephalopathy. *Rom J Virol.* 1998; 49:61–71. [PubMed: 10892427]
- Rychert J, Strick D, Bazner S, et al. Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines. *AIDS Res Hum Retroviruses.* 2010; 26:1139–1145. DOI: 10.1089/aid.2009.0290 [PubMed: 20722464]
- Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. *J Neurovirol.* 2002; 8:136–142. DOI: 10.1080/13550280290049615 [PubMed: 11935465]
- Santosuosso M, Righi E, Lindstrom V, et al. HIV-1 envelope protein gp120 is present at high concentrations in secondary lymphoid organs of individuals with chronic HIV-1 infection. *J Infect Dis.* 2009; 200:1050–1053. DOI: 10.1086/605695 [PubMed: 19698075]
- Toggas SM, Masliah E, Rockenstein EM, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. *Nature.* 1994; 367:188–193. DOI: 10.1038/367188a0 [PubMed: 8114918]

- Trujillo JR, Navia BA, Worth J, et al. High levels of anti-HIV-1 envelope antibodies in cerebrospinal fluid as compared to serum from patients with AIDS dementia complex. *J Acquir Immune Defic Syndr Hum Retrovirology Off Publ Int Retrovirology Assoc.* 1996; 12:19–25.
- van der Zanden EP, Hilbers FW, Verseijden C, et al. Nicotinic acetylcholine receptor expression and susceptibility to cholinergic immunomodulation in human monocytes of smoking individuals. *Neuroimmunomodulation.* 2012; 19:255–265. DOI: 10.1159/000335185 [PubMed: 22441542]
- von Giesen HJ, Wittsack HJ, Wenserski F, et al. Basal ganglia metabolite abnormalities in minor motor disorders associated with human immunodeficiency virus type 1. *Arch Neurol.* 2001; 58:1281–1286. [PubMed: 11493169]
- Wang Y, Xiao C, Indersmitten T, et al. The Duplicated $\alpha 7$ Subunits Assemble and Form Functional Nicotinic Receptors with the Full-length $\alpha 7$. *J Biol Chem.* 2014; 289:26451–26463. DOI: 10.1074/jbc.M114.582858 [PubMed: 25056953]
- Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. *Neuropsychol Rev.* 2009; 19:152–168. DOI: 10.1007/s11065-009-9102-5 [PubMed: 19462243]
- Xu Y, Kulkosky J, Acheampong E, et al. HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy. *Proc Natl Acad Sci U S A.* 2004; 101:7070–7075. DOI: 10.1073/pnas.0304859101 [PubMed: 15103018]
- Zheng J, Thylin MR, Ghorpade A, et al. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. *J Neuroimmunol.* 1999; 98:185–200. [PubMed: 10430052]





Fig. 1. gp120_{IIIB} induces the downregulation of *CHRFA7A* in neuronal cells. **a** Neuronal cells were incubated with gp120_{IIIB} 0.0015, 0.015, 0.15, 1.5 and 15.0 nM for 12 hours. A downregulation of *CHRFA7A* was observed under pathophysiological (0.015 and 0.15 nM) and supraphysiological doses (15 nM). **b** *CHRNA7:CHRFA7A* expression ratio shows a significant increase under pathophysiological and supraphysiological conditions as compared to control. In panel a and b, results were normalized to control. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Statistical analysis: One-way ANOVA followed by Holm-Sidak's multiple comparison tests, error bars represents SEM. For all panels $n = 4$ independent experiments.

**Fig. 2.**

Time-dependent responses of *CHRNA7* and *CHRFA7A* in neuronal cells exposed to HIV-1-gp120_{IIIb}. **a** Neuronal cells were incubated with gp120_{IIIb} (0.15 nM) at various time points. As compared to untreated control cells, downregulation of *CHRFA7A* was observed at all-time points while *CHRNA7* was upregulated after 12 hours of gp120_{IIIb} application. **b** *CHRNA7*:*CHRFA7A* expression ratio showed a significant increase after 15 min, 12h, and 24h post gp120_{IIIb} application. Results were normalized and compared to control cells. **P* 0.05, ***P* 0.01, ****P* 0.001. *n* = 4 independent experiments. Statistical analysis: One-way ANOVA followed by Holm-Sidak's multiple comparison test.




Fig. 3. Dysregulation of the *CHRFAM7A:CHRNA7* ratio by gp120_{III B} is dependent on CXCR4-gp120 interaction. Neuronal cells were incubated with 0.15 nM gp120_{III B} for 12 hours with and without a pre-incubation of AMD3100. The *CHRNA7* upregulation induced by gp120_{III B} was obliterated by AMD3100 treatment. AMD3100 treatment alone downregulates the *CHRFAM7A*. Results were normalized and compared to control cells. * $P < 0.05$, ** $P < 0.01$. $n = 3$ independent experiments. Statistical analysis: One way ANOVA followed by a Holm-Sidak's multiple comparison tests.




Fig. 4. Dysregulation of the *CHRFAM7A* transcript in the basal ganglia of HIV+ individuals. **a** HIV-infected subjects exhibited significant higher levels of *CHRNA7*, HIV- ($n = 5$), HIV+ ($n = 31$). **b** *CHRNA7:CHRFAM7A* expression ratio appears higher in HIV-infected subjects HIV+ ($n = 5$), HIV- ($n = 31$). **c** Analysis of *CHRNA7* mRNA levels in HIV-infected individuals. For control $n = 5$, normal cognition $n = 13$, MCMD $n = 9$, and HAD $n = 11$. **d** Two subgroups of HIV+ individuals with normal cognition exhibited different responses in *CHRFAM7A* regulation and are significantly different when compared to HIV- individuals. For control $n = 5$, normal cognition $n = 16$, subgroup A $n = 7$, and sub-group B $n = 9$. **e** No significant changes were detected in *CHRFAM7A* levels in MCMD or HAD suffering patients when compared to HIV- whereas normal cognition subgroups are significant different from HIV- subjects. For control $n = 5$, sub-group A $n = 7$, and sub-group B $n = 9$, MCMD $n = 9$, and HAD $n = 13$. **f** Analysis of variance followed by a linear trend test comparing all groups ($P = 0.08$). For control $n = 5$, normal cognition $n = 10$, MCMD $n = 9$, and HAD $n = 12$. For all panels, results were normalized to HIV- individuals. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Table 1
Subject characteristics

	HIV –		HIV +	
	(n = 5)	Normal Cognition (n = 16)	MCMD (n = 9)	HAD (n = 13)
* Age (years)	51.0 (48.0, 51.0)	53.0 (46.0, 59.0)	44.0 (40.5, 58.5)	51.0 (44.5, 54.5)
Gender	5 male	15 male/1 female	9 male	13 male
Treatment	N/A	RTV (1), 3TC (5), CBV (1), DRV (1), NVP (1), ABC (1), NA (6)	RTV (1), APV (1), CBV (2), 3TC (1), NA (4)	ZVD (1), FTC (1), RTV (1), APV (1), CBV (1), EFV (1), ABC (1), 3TC (1), NA (5)
Viral-immune profile				
* CD4 cell count (cells/mm ³)	NA	171.0 (18.0, 352.0)	26.5 (7.8, 159.8)	247.0 (25.0, 365.0)
* Plasma HIV RNA (log 10)	N/A	4.6 (2.6, 5.2)	5.1 (4.3, 5.8)	4.3 (2.6, 5.1)

* Values presented as median (25th, 75th percentiles)

N/A = not applicable

NA = information not available

RTV = ritonavir (Norvir), 3TC = lamivudine (EpiVir), CBV = zidovudine + lamivudine (Combivir), DRV = TMC-114, darunavir (Prezista), NVP = nevirapine (Viramune), ABC = abacavir (Ziagen), APV = amprenavir (Agenerase), CBV = zidovudine + lamivudine (Combivir), ZDV = AZT, zidovudine (Retrovir), FTC = emtricitabine (Coviracil; Emtriva), EFV = efavirenz (Sustiva).